AccuStem Sciences, Inc. (ACUT)
OQB · Healthcare · Biotechnology
$0.26
+0.00%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$4.1M
Shares Outstanding
16.1M
Exchange
OQB
Currency
USD
About AccuStem Sciences, Inc.
AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. The company offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. It also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -401K | -400K | -514K | -486K |
| Net Income | -401K | -400K | -514K | -486K |
| Diluted EPS | $-0.02 | $-0.02 | $nan | $-0.03 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -3.7M | -2.1M | -1.5M | -1.8M |
| Net Income | -3.7M | -2.1M | -1.5M | -1.8M |
| Diluted EPS | $-0.34 | $-0.18 | $-0.13 | $-0.12 |